ALS2CR16 inhibitors are a class of chemical compounds designed to specifically inhibit the activity of the ALS2CR16 protein, encoded by the ALS2CR16 gene. While the precise biological function of ALS2CR16 remains under investigation, it is thought to be involved in various cellular processes, possibly related to molecular signaling, protein-protein interactions, or structural functions within cells. Inhibitors of ALS2CR16 typically work by binding to the protein's active site or regulatory domains, effectively blocking its interaction with other molecules or preventing it from executing its normal cellular functions. These inhibitors are usually designed to mimic the natural substrates or binding partners of ALS2CR16, allowing them to compete with these molecules for the active site. Structural features of ALS2CR16 inhibitors may include hydrophobic regions, aromatic rings, or functional groups that interact with key residues on the protein through hydrogen bonding, hydrophobic interactions, or electrostatic forces.
The development of ALS2CR16 inhibitors relies heavily on a detailed understanding of the protein's three-dimensional structure, often derived from techniques like X-ray crystallography or cryo-electron microscopy. By analyzing the spatial arrangement of the protein's active and regulatory regions, researchers can identify critical binding sites and design inhibitors that precisely target these regions. Computational tools, such as molecular docking and dynamics simulations, play a crucial role in predicting how well these inhibitors will bind to ALS2CR16 and in optimizing their affinity and selectivity. Some ALS2CR16 inhibitors may act through allosteric mechanisms, binding to regions of the protein that are distant from the active site but inducing conformational changes that reduce its overall activity. These inhibitors are valuable tools for studying the role of ALS2CR16 in various cellular processes, providing insight into its molecular interactions and contributions to cellular pathways. Through the use of ALS2CR16 inhibitors, researchers can explore the fundamental functions of this protein and its role in the regulation of biological systems.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Inhibits a broad spectrum of protein kinases, which can interfere with phosphorylation-dependent signaling pathways that regulate ALS2CR16 activity or stability. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
Inhibits PI3K, disrupting PI3K/Akt signaling which can modulate ALS2CR16 either through direct phosphorylation or through secondary signaling effects. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
Inhibits p38 MAPK, potentially altering stress response or inflammatory signaling pathways that can influence ALS2CR16 activity. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
Inhibits the proteasome, leading to an accumulation of proteins and possibly affecting ALS2CR16 by altering the degradation of proteins that regulate its activity. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $188.00 $575.00 | 60 | |
Inhibits the proteasome, leading to increased levels of proteins within the cell which can impact ALS2CR16 function by modulating its interacting partners. | ||||||
Cyclosporin A | 59865-13-3 | sc-3503 sc-3503-CW sc-3503A sc-3503B sc-3503C sc-3503D | 100 mg 100 mg 500 mg 10 g 25 g 100 g | $63.00 $92.00 $250.00 $485.00 $1035.00 $2141.00 | 69 | |
Inhibits calcineurin, potentially affecting ALS2CR16 by changing the phosphorylation status of proteins that interact with or regulate it. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
Inhibits SERCA, affecting calcium homeostasis, which can alter the activity of ALS2CR16 if it is regulated by calcium-dependent mechanisms. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
Inhibits MEK, which can affect ALS2CR16 activity indirectly by modulating the phosphorylation status of proteins in the MAPK/ERK pathway. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Inhibits PI3K, affecting signaling pathways that can have a downstream impact on the regulation of ALS2CR16. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Inhibits the proteasome, which can affect ALS2CR16 by altering the stability and turnover of regulatory proteins within the cell. | ||||||